On Invalid Date, Allogene Therapeutics (NASDAQ: ALLO) reported Q4 2023 earnings per share (EPS) of -$0.54, up 23.94% year over year. Total Allogene Therapeutics earnings for the quarter were -$89.26 million. In the same quarter last year, Allogene Therapeutics's earnings per share (EPS) was -$0.71.
As of Q1 2024, Allogene Therapeutics's earnings has grown year over year. Allogene Therapeutics's earnings in the past year totalled -$327.27 million.
What is ALLO's earnings date?
Allogene Therapeutics's earnings date is Invalid Date. Add ALLO to your watchlist to be reminded of ALLO's next earnings announcement.
What was ALLO's revenue last quarter?
On Invalid Date, Allogene Therapeutics (NASDAQ: ALLO) reported Q4 2023 revenue of -$44.00 thousand up 10% year over year. In the same quarter last year, Allogene Therapeutics's revenue was -$40.00 thousand.
What was ALLO's revenue growth in the past year?
As of Q1 2024, Allogene Therapeutics's revenue has grown -39.1% year over year. This is 208.4 percentage points lower than the US Biotechnology industry revenue growth rate of 169.3%. Allogene Therapeutics's revenue in the past year totalled $95.00 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.